Medical Oncology Unit, Department of General & Specialistic Medicine, University Hospital of Parma, Via Gramsci 14, 43126 Parma, Italy.
Department of Medicine & Surgery, Unit of Pathological Anatomy, University Hospital of Parma, Via Gramsci 14, 43126 Parma, Italy.
Immunotherapy. 2020 Feb;12(3):183-193. doi: 10.2217/imt-2019-0138. Epub 2020 Feb 18.
Programmed cell death-ligand 1 (PD-L1) predicts response to immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) patients. Most NSCLCs are diagnosed at an advanced stage and using minimally invasive diagnostic procedures that yield small biopsies or cytological samples. Cytological smears and paired histological samples from 52 advanced NSCLC patients were tested for PD-L1 expression by immunocyto/histochemistry (ICC/IHC) and for gene status by FISH. was overexpressed in 9/52 (17%) cytological samples and in seven (13.5%) matched biopsies. The concordance between immunocytochemistry and IHC was 92.3% (48/52; p < 0.001). The concordance between gene status on cytology and histology was 69.2% (18/26; p < 0.001). No correlation between IHC and fluorescence hybridization results was found. Our data support the feasibility and reliability of PD-L1 protein and gene assessment on direct cytological smears from NSCLC patients whenever histological sample are inadequate.
程序性死亡配体 1（PD-L1）可预测非小细胞肺癌（NSCLC）患者对免疫检查点抑制剂的反应。大多数 NSCLC 是在晚期诊断的，使用微创诊断程序会产生小的活检或细胞学样本。对 52 例晚期 NSCLC 患者的细胞学涂片和配对组织学样本进行免疫细胞化学/免疫组织化学（ICC/IHC）检测 PD-L1 表达，并通过 FISH 检测 基因状态。在 9/52（17%）例细胞学样本和 7（13.5%）例匹配活检中发现过度表达。免疫细胞化学与免疫组织化学的一致性为 92.3%（48/52;p<0.001）。细胞学和组织学上 基因状态的一致性为 69.2%（18/26;p<0.001）。未发现 IHC 与荧光原位杂交结果之间存在相关性。我们的数据支持在组织学样本不足时，对 NSCLC 患者的直接细胞学涂片进行 PD-L1 蛋白和 基因评估的可行性和可靠性。
